Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
binimetinib + ganitumab
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Binimetinib + ganitumab is an investigational combination therapy pairing the small‑molecule MEK1/2 inhibitor binimetinib with the monoclonal antibody ganitumab, which targets the insulin‑like growth factor 1 receptor. The rationale is to concurrently inhibit MAPK pathway signaling downstream via MEK and upstream growth signaling via IGF‑1R to overcome resistance and enhance antitumor activity in advanced solid tumors. A phase 1b/2 trial (NCT01562899) was designed to establish a safe and tolerated dose of binimetinib in combination with ganitumab in selected advanced solid tumors; the study was later reported as terminated for nonmedical reasons. Binimetinib is marketed separately for other indications, whereas ganitumab has been developed as an anti‑IGF-1R antibody in oncology trials.[5][6]
- Other names
- MEK162 + AMG 479binimetinib + AMG 479
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)
Beyond the preview
Go deeper on binimetinib + ganitumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on binimetinib + ganitumab.